179 related articles for article (PubMed ID: 36250317)
1. Late toxicity comparison of alkylating-based maintenance regimen with cyclophosphamide (VAC) vs ifosfamide (VAI) in Ewing sarcoma survivors treated in the randomized clinical trial Euro-EWING99-R1 in France.
Corvest V; Marec-Bérard P; Lervat C; Pacquement H; Toulmonde M; Gentet JC; Laurence V; Cleirec M; Mansuy L; Bompas E; Castex MP; Taque S; Filhon B; Tabone MD; Verité C; Entz-Werle N; Saumet L; Guimard G; Pondrom M; Chevreau C; Flandrin J; Duranteau L; Rousset-Jablonski C; Brugières L; Jimenez M; Le Deley MC; Gaspar N; Fresneau B
Int J Cancer; 2023 Apr; 152(8):1659-1667. PubMed ID: 36250317
[TBL] [Abstract][Full Text] [Related]
2. Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial.
Le Deley MC; Paulussen M; Lewis I; Brennan B; Ranft A; Whelan J; Le Teuff G; Michon J; Ladenstein R; Marec-Bérard P; van den Berg H; Hjorth L; Wheatley K; Judson I; Juergens H; Craft A; Oberlin O; Dirksen U
J Clin Oncol; 2014 Aug; 32(23):2440-8. PubMed ID: 24982464
[TBL] [Abstract][Full Text] [Related]
3. Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial.
van den Berg H; Paulussen M; Le Teuff G; Judson I; Gelderblom H; Dirksen U; Brennan B; Whelan J; Ladenstein RL; Marec-Berard P; Kruseova J; Hjorth L; Kühne T; Brichard B; Wheatley K; Craft A; Juergens H; Gaspar N; Le Deley MC;
Eur J Cancer; 2015 Nov; 51(16):2453-64. PubMed ID: 26271204
[TBL] [Abstract][Full Text] [Related]
4. International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours - EURO EWING 2012 Protocol.
Anderton J; Moroz V; Marec-Bérard P; Gaspar N; Laurence V; Martín-Broto J; Sastre A; Gelderblom H; Owens C; Kaiser S; Fernández-Pinto M; Fenwick N; Evans A; Strauss S; Whelan J; Wheatley K; Brennan B
Trials; 2020 Jan; 21(1):96. PubMed ID: 31952545
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
Brennan B; Kirton L; Marec-Bérard P; Gaspar N; Laurence V; Martín-Broto J; Sastre A; Gelderblom H; Owens C; Fenwick N; Strauss S; Moroz V; Whelan J; Wheatley K
Lancet; 2022 Oct; 400(10362):1513-1521. PubMed ID: 36522207
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of Treating Adults with Ewing or Ewing-Like Sarcoma with Interval-Compressed Vincristine, Doxorubicin, and Cyclophosphamide Alternating with Ifosfamide and Etoposide.
Lu E; Ryan CW; Bassale S; Lim JY; Davis LE
Oncologist; 2020 Feb; 25(2):150-155. PubMed ID: 32043790
[TBL] [Abstract][Full Text] [Related]
7. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study.
Granowetter L; Womer R; Devidas M; Krailo M; Wang C; Bernstein M; Marina N; Leavey P; Gebhardt M; Healey J; Shamberger RC; Goorin A; Miser J; Meyer J; Arndt CA; Sailer S; Marcus K; Perlman E; Dickman P; Grier HE
J Clin Oncol; 2009 May; 27(15):2536-41. PubMed ID: 19349548
[TBL] [Abstract][Full Text] [Related]
8. High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008.
Dirksen U; Brennan B; Le Deley MC; Cozic N; van den Berg H; Bhadri V; Brichard B; Claude L; Craft A; Amler S; Gaspar N; Gelderblom H; Goldsby R; Gorlick R; Grier HE; Guinbretiere JM; Hauser P; Hjorth L; Janeway K; Juergens H; Judson I; Krailo M; Kruseova J; Kuehne T; Ladenstein R; Lervat C; Lessnick SL; Lewis I; Linassier C; Marec-Berard P; Marina N; Morland B; Pacquement H; Paulussen M; Randall RL; Ranft A; Le Teuff G; Wheatley K; Whelan J; Womer R; Oberlin O; Hawkins DS;
J Clin Oncol; 2019 Dec; 37(34):3192-3202. PubMed ID: 31553693
[TBL] [Abstract][Full Text] [Related]
9. Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group.
Bhatia S; Krailo MD; Chen Z; Burden L; Askin FB; Dickman PS; Grier HE; Link MP; Meyers PA; Perlman EJ; Rausen AR; Robison LL; Vietti TJ; Miser JS
Blood; 2007 Jan; 109(1):46-51. PubMed ID: 16985182
[TBL] [Abstract][Full Text] [Related]
10. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial.
Juergens C; Weston C; Lewis I; Whelan J; Paulussen M; Oberlin O; Michon J; Zoubek A; Juergens H; Craft A
Pediatr Blood Cancer; 2006 Jul; 47(1):22-9. PubMed ID: 16572419
[TBL] [Abstract][Full Text] [Related]
11. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group.
Womer RB; West DC; Krailo MD; Dickman PS; Pawel BR; Grier HE; Marcus K; Sailer S; Healey JH; Dormans JP; Weiss AR
J Clin Oncol; 2012 Nov; 30(33):4148-54. PubMed ID: 23091096
[TBL] [Abstract][Full Text] [Related]
12. Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study).
Fresneau B; Hackshaw A; Hawkins DS; Paulussen M; Anderson JR; Judson I; Litière S; Dirksen U; Lewis I; van den Berg H; Gaspar N; Gelderblom H; Whelan J; Boddy AV; Wheatley K; Pignon JP; De Vathaire F; Le Deley MC; Le Teuff G
Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28111876
[TBL] [Abstract][Full Text] [Related]
13. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Paulussen M; Craft AW; Lewis I; Hackshaw A; Douglas C; Dunst J; Schuck A; Winkelmann W; Köhler G; Poremba C; Zoubek A; Ladenstein R; van den Berg H; Hunold A; Cassoni A; Spooner D; Grimer R; Whelan J; McTiernan A; Jürgens H;
J Clin Oncol; 2008 Sep; 26(27):4385-93. PubMed ID: 18802150
[TBL] [Abstract][Full Text] [Related]
14. Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience.
Navid F; Santana VM; Billups CA; Merchant TE; Furman WL; Spunt SL; Cain AM; Rao BN; Hale GA; Pappo AS
Cancer; 2006 Apr; 106(8):1846-56. PubMed ID: 16541446
[TBL] [Abstract][Full Text] [Related]
15. Second malignancies after ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study.
Paulussen M; Ahrens S; Lehnert M; Taeger D; Hense HW; Wagner A; Dunst J; Harms D; Reiter A; Henze G; Niemeyer C; Göbel U; Kremens B; Fölsch UR; Aulitzky WE; Voûte PA; Zoubek A; Jürgens H
Ann Oncol; 2001 Nov; 12(11):1619-30. PubMed ID: 11822764
[TBL] [Abstract][Full Text] [Related]
16. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial.
Ladenstein R; Pötschger U; Le Deley MC; Whelan J; Paulussen M; Oberlin O; van den Berg H; Dirksen U; Hjorth L; Michon J; Lewis I; Craft A; Jürgens H
J Clin Oncol; 2010 Jul; 28(20):3284-91. PubMed ID: 20547982
[TBL] [Abstract][Full Text] [Related]
17. Vincristine, doxorubicin, cyclophosfamide, actinomycin D, ifosfamide, and etoposide in adult and pediatric patients with nonmetastatic Ewing sarcoma. Final results of a monoinstitutional study.
Ferrari S; Palmerini E; Alberghini M; Staals E; Mercuri M; Barbieri E; Longhi A; Cantero L; Cesari M; Abate M; Balladelli A; Picci P; Bacci G
Tumori; 2010; 96(2):213-8. PubMed ID: 20572576
[TBL] [Abstract][Full Text] [Related]
18. Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity.
Ferrari S; Mercuri M; Rosito P; Mancini A; Barbieri E; Longhi A; Rimondini S; Cesari M; Ruggieri P; Di Liddo M; Bacci G
J Chemother; 1998 Dec; 10(6):484-91. PubMed ID: 9876058
[TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response.
Ruymann FB; Vietti T; Gehan E; Wiener E; Wharam M; Newton WA; Maurer H
J Pediatr Hematol Oncol; 1995 Nov; 17(4):331-7. PubMed ID: 7583389
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy for Ewing's sarcoma of bone: no benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase--results of two sequential studies.
Bacci G; Picci P; Ferrari S; Mercuri M; Brach del Prever A; Rosito P; Barbieri E; Tienghi A; Forni C
Cancer; 1998 Mar; 82(6):1174-83. PubMed ID: 9506366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
